Skip to content
10-Q

Quarterly Report

TScan Therapeutics, Inc. TCRX

0001193125-26-207572

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 129.91M sh
Shares Diluted Q1 2026 · Mar 31, 2025 129.68M sh
Capex Q1 2026 · Mar 31, 2026 $70K
Capex Q1 2026 · Mar 31, 2025 $1.53M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$24.28M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$37.59M
Long Term Debt Q1 2026 · Mar 31, 2026 $32.65M
Long Term Debt Q1 2026 · Dec 31, 2025 $32.53M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $128.06M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $152.41M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $154.11M
Stockholders Equity Q1 2026 · Mar 31, 2026 $96.92M
Stockholders Equity Q1 2026 · Dec 31, 2025 $123.12M
Stockholders Equity Q1 2026 · Mar 31, 2025 $210.2M
Stockholders Equity Q1 2026 · Dec 31, 2024 $240.97M
Current Liabilities Q1 2026 · Mar 31, 2026 $19.97M
Current Liabilities Q1 2026 · Dec 31, 2025 $18.7M
Total Liabilities Q1 2026 · Mar 31, 2026 $105.07M
Total Liabilities Q1 2026 · Dec 31, 2025 $105.67M
Current Assets Q1 2026 · Mar 31, 2026 $132.77M
Current Assets Q1 2026 · Dec 31, 2025 $157.21M
Total Assets Q1 2026 · Mar 31, 2026 $201.99M
Total Assets Q1 2026 · Dec 31, 2025 $228.79M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.22
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.26
Eps Basic Q1 2026 · Mar 31, 2026 −$0.22
Eps Basic Q1 2026 · Mar 31, 2025 −$0.26
Sga Expense Q1 2026 · Mar 31, 2026 $8.22M
Sga Expense Q1 2026 · Mar 31, 2025 $8.63M
Rd Expense Q1 2026 · Mar 31, 2026 $21.9M
Rd Expense Q1 2026 · Mar 31, 2025 $29.79M
Net Income Q1 2026 · Mar 31, 2026 −$28.67M
Net Income Q1 2026 · Mar 31, 2025 −$34.13M
Operating Income Q1 2026 · Mar 31, 2026 −$29.14M
Operating Income Q1 2026 · Mar 31, 2025 −$36.25M
Revenue Q1 2026 · Mar 31, 2026 $982K
Revenue Q1 2026 · Mar 31, 2025 $2.17M